https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-23 08:41:062024-02-07 08:43:00Novo Holdings announces pre-IPO investment in Medi Assist, the top health benefits’ administrator in India
https://www.optimumcomms.com/wp-content/uploads/2023/06/Novo_Holdings23_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2024-01-23 08:41:062024-02-07 08:43:00Novo Holdings announces pre-IPO investment in Medi Assist, the top health benefits’ administrator in India
Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510
Synendos Therapeutics transitions to a clinical-stage biotech…

Poolbeg Pharma plc – Further Data Confirms POLB 001’s Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)
Market opportunity estimated to be greater than US$1 billion
Key…

AMSilk and 21st.BIO announce partnership to accelerate the production of advanced materials made from spider silk-based proteins
New protein production strain delivers unprecedented yield with…

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing
Transformative surfaceome discovery technology enables a…

Biocomposites expands its international presence by opening new sales and distribution office in Italy
Biocomposites SRL will support sales of STIMULAN, NanoBone,…

DelSiTech Announces Closing of EUR 10 Million Financing Round to Advance its Silica-Based Drug Delivery Technology Platform
New investment from DRW Venture Capital LLC and Tolmar International…

Futura Medical extends collaboration with Cooper Consumer Health
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the…

Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to test its First-in-Class Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma
Berlin, Germany, 10th January 2024 – Ariceum Therapeutics,…

Novo Nordisk Foundation partners with CARB-X to fight drug-resistant infections
COPENHAGEN, Denmark, Jan. 9, 2024 - The Novo Nordisk Foundation…

Futura Medical plc – Appointment of Roy Davis as Non-Executive Director
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the…

Revagenix, Inc. Announces Series B Financing to Develop Novel Antibiotics and Additions to its Board of Directors
Tenmile and Novo Holdings are…

2023 Novo Holdings Seed Investments Team Annual Review/Business Update
Several significant portfolio financing rounds
Launch…

Biocomposites’ investee Renovos Biologics receives FDA Breakthrough Device Designation for its synthetic nanoclay bone fusion gel, RENOVITE® BMP-2
RENOVITE® BMP-2 is being developed as an alternative to…

Vicore Reports Positive Results for the Pivotal Study of its Digital Therapy for Patients with Pulmonary Fibrosis
The COMPANION pivotal study met the primary endpoint and…

SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer
Dr. Girach is a world-renowned specialist in the field…

Vicore Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates
Development of C21 in IPF on track; final Phase 2a AIR data…

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
NEW YORK, December 21, 2023 (GLOBE NEWSWIRE) – IO Biotech (Nasdaq:…

Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX)…

European Commission revokes all centrally granted generic marketing permissions for dimethyl fumarate (“DMF”), including Dimethyl Fumarate Neuraxpharm
Decision is not due to any public health concerns regarding generic…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York